



Kassis et al General Thoracic SurgerySeveral controversies will undoubtedly arise with the
adoption of the IASLC staging system.
In the current UICC-6 system, T4 lesions are staged as
IIIB regardless of lymph node status and are considered
unresectable except in special circumstances. In this study,
shifting of stage with application of the IASLC may poten-
tially alter the management of 134 (11.6%) patients. Sixty-
three of these patients were upstaged from a stage where
surgery alone is the recommended treatment to a stage where
adjvant chemotherapy may be considered.13-15 Additionally,
10 patients were upstaged to a stage where neoadjuvant che-
motherapy is frequently offered (stage II to IIIA). The role of
adjuvant and neoadjuvant chemotherapy in these patient
populations may need to be re-evaluated. The IASLC system
T4 lesions would be considered as IIIA or IIIB and the des-
ignation is based on the presence of absence of mediastinal
nodal metastases. Satellite nodules in the ipsilateral primary
lobe are considered unresectable T4 (stage IIIB) disease by
UICC-6 criteria but T3 (stage IIB or IIIA) and potentially
resectable by IASLC. Additionally, a satellite nodule in
the ipsilateral lung but outside the primary lobe is unresect-
able M1 (stage IV) in the UICC-6 system and potentially re-
sectable T4 (stage IIIA or IIIB) by IASLC. The optimal
treatment strategy for these stages needs to be re-evaluated.
Further study and validation of IASLC staging system and
its effects on patient care are warranted.
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Discussion
Dr Bryan Fitch Meyers (St. Louis, Mo). I congratulate Dr Kas-
sis on his presentation. Because there were not any photographs of
aortas or mitral valves, I am going to use some of my time to under-
score some of his findings and elaborate a little bit, then follow up
with two short questions.
First of all, the old system was created using 5000 patients, 90%
of them from a single center, M. D. Anderson, where Dr Kassis is
working right now. The new system was created using morethan
100,000 patients collected worldwide, and it really is an interna-
tional effort to represent uniform staging for patients with lung
cancer. Twenty-eight thousand of those patients actually had
a thoracotomy. This major revision has expanded the ability to
make clear statements about staging.
If we assume that these proposed changes are meaningful and
important changes based on 28,000 operated patients, then what
conclusions would be drawn on the basis of the results of a confir-
matory study like this? First, we would either be reassured or raise
some doubt that the M. D. Anderson method of selecting patients
and treating patients is consistent with those done in the rest of
the world. If we assume that the M. D. Anderson system is repre-
sentative of North America or American techniques, if these results
were discrepant with the findings of the international group, we
would wonder whether North America or America is distinct
from other groups. Fortunately, your results are reassuring in that
they confirm the recommendations by the international group.
It turns out that the findings that interest us most in a staging sys-
tem are three things. What we want to see when one makes a change
in a staging system, particularly a long awaited change like this, is
that patients do shift from one stage to another. Dr Kassis has men-
tioned that 17% of the patients were shifted from one stage to an-
other, and whether you use a P value or not, that is a substantial
and clinically important change in the way that patients were as-
signed a stage. That number in itself tells us this was a meaningful
change. The other aspects that are important are the distinctiveness
of the stage groups and the heterogeneity within each stage group.
If you look at Dr Kassis’ slide of the old system, with the stage
IIA curve crossing over the IIB and then crossing over the IB, there
is deficiency in the distinctiveness of the curves. However, if you
move to the next slide where they applied the new staging system
to their own data, you see that that distinctiveness has been im-
proved with the new system. So, again, his presentation shows




General Thoracic Surgery Kassis et alOne area that was lacking in your presentation and discussion
pertains to the problem of heterogeneity within each stage group.
Is there a way that you could add to these results that reassures
us that the patients who moved were moved from a group where
they were less representative to a group that they now are more rep-
resentative and homogeneous in their new stage group?
Dr Kassis. We did not definitively look at heterogeneity be-
tween stages, although that is a very good question and something
that we could certainly evaluate at a future time. What we did do,
though, is attempt to look at Kaplan–Meier curves in terms of strat-
ifying these patients based on their ability to differentiate patients
on the basis of stage. We took it one step further to try and do a sta-
tistical assessment of these patients by using a model called the per-
mutation test to help quantify the differences that we see based on
the Kaplan–Meier curve. However, your question regarding hetero-
geneity is something that we need to look at in the future.
DrMeyers. The other question I had for you is that when we do
a model, either a predictive or a descriptive model, and we want to
validate it, we often use cases that were not used to create the
model, and this was not mentioned in your presentation or the pa-
per. Did the M. D. Anderson patients who were presented here play
a role in the 28,000 operated patients who were used to create this
new model? What are your thoughts on the impact of your answer
on the importance of these results?
Dr Kassis. Less than 10% of our patient population of the 1154
patients was analyzed by the IASLC system, and the length of fol-
low-up was such that in our estimation they are two completely
separate data sets.
Dr Frank C. Detterbeck (New Haven, Conn). I just have
a comment. I think that we need to be careful about what we418 The Journal of Thoracic and Cardiovascular Suare trying to get from this. There are many purposes to a staging
system. One is to have a nomenclature so that when one person is
talking about certain patients in one study and another person is
talking about them in another institution, the same group of pa-
tients are being discussed. Another is to determine prognosis,
and that is clearly what was chosen as the primary goal in the
IASLC staging project. And clearly it meets that goal. I think
a third one, which is to select appropriate treatment for patients,
is a bit of a slippery slope. That is not what the IASLC staging
project was designed to do and it is not what staging systems
are designed to do. Now, we use the language to help us talk
about it, but it is really clinical trials that define what the appro-
priate treatment is for patients. We cannot just identify a stage (eg,
stage II) and base treatment merely on that. We have to look at
which patients we are talking about and what the clinical trials
have shown us that we should be doing.
I think that you are taking the stage classification system to a dif-
ferent realm here than what it was intended to do, and I am not sure
that that is really appropriate.
Dr Kassis. Thank you for your comments. I do agree with you. I
do not think that we should be altering patient management on the
basis of the stage shifting that we have demonstrated here. What I
am trying to demonstrate is that the shifting of patients may lead to
further studies so that we can better assess and better determine
what to do with these patients with a satellite nodule in the ipsilat-
eral lobe that was formerly T4 in stage IIIB disease. In the current
system, if they are N0, they are going to be stage IIB; if they are N1,
they are going to be stage IIIA. I think we need further studies to
evaluate how we are going to manage these patients now that are
assigned different stage groupings.rgery c August 2009
